is metformin a glp 1 receptor agonist Diagram summarizing how metformin, gliclazide, GLP-1 agonists, Comparing Glucagon‐like peptide‐1 receptor agonists

These therapies display higher efficiency compared to classical senolytic drugs (BCL-2 or tyrosine kinase inhibitors) but for some of them, such as NA + /K + ATPase inhibitors, clinical development could be complex in the light of strong cardiotoxicity associated with this class of molecules

Consistent use of high-quality supplements is key, and many individuals report a noticeable difference after 4 to 8 weeks of regular use

Some key players have been well-characterized, but other aspects of the signalling mechanisms involved are still unclear

doi: 10.1016/j.sleep.2024.01.030, 19

Now I wear shorts without thinking twice

Table 1 Summary of the cardiovascular protective effects exerted by SIN